Watson Pharmaceuticals Incorporated 

WPI:NYSE

LastChange / % ChangeDividend YieldVolume
51.87 -0.4400   -0.84%0.00%1,084,448

Market data is delayed by at least 20 minutes.

Exclusive Features

When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes.

For full analysis details, Log In with Scottrade or you can:
  •  
    Advanced Charts

  •  
    Embed Chart

    Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

  • 1 Day
  • 5 Day
  • 6 Mo
  • 1 Yr
  • 5 Yr
 
 
 

Latest News Headlines for Watson Pharmaceuticals Incorporated

Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
4 days 12 hours 34 minutes ago - PR Newswire
Reportlinker.com announces that a new market research report is available in its catalogue: Watson Pharmaceuticals Inc.: PharmaVitae Profile http://www.reportlinker.com/p0171756/Watson-Pharmaceuticals-Inc-PharmaVitae-Profile.html
Watson Pharmaceuticals Sees Earnings Above Estimates
5 days 12 hours 30 minutes ago - EarningsWhispers Earnings Guidance
Watson Pharmaceuticals, Inc. (NYSE: WPI) said it expects 2010 earnings to be at, or slightly above, the mid-point of its previous guidance range of $3.37 to $3.45 per share. The current consensus earnings estimate is $3.40 per share for the year ending December 31, 2010.
Watson Announces Preliminary Financial Performance for FY 2010
5 days 12 hours 48 minutes ago - PR Newswire
At the 29th Annual J.P. Morgan Healthcare Conference, Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that based on a preliminary review of 2010 results, it expects net revenues to increase more than 25 percent to more than $3.5 billion compared to 2009. Adjusted cash earnings per share is expected to be at or slightly above the midpoint of the company's latest forecast of $3.37 to $3.45 per share, a greater than 12 percent increase over 2009. This is based on a preliminary review of the Company's operating results for the fourth quarter and year-ended December 31, 2010.
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
March 1, 2010
This report contains detailed information about the company's business finances and management.
10-Q
November 5, 2010
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products. Watson operates manufacturing, distribution, research and development (R&D;), and administrative facilities in the United States of America. Watson operates and manages its business as three operating segments: Generic, Brand and Distribution. As of December 31, 2009, the Company marketed approximately 170 generic pharmaceutical product families and 30 brand pharmaceutical product families and distributed approximately 8,000 stock-keeping units (SKUs) through its Distribution business in the United States. On December 2, 2009, Watson completed the acquisition of Robin Hood Holdings Limited and Cobalt Laboratories, Inc. On November 26, 2009, the Company acquired Arrow Group. Watson also acquired a 36% ownership interest in Eden Biopharm Group (Eden).
Bid/Size
-- / --
Ask/Size
-- / --
Price Open
52.14
Previous Close
52.31
Day High
52.20
Day Low
51.39
52wk High/Date
53.75 / 1/11/2011
52wk Low/Date
37.26 / 2/12/2010
Beta
0.47
Market Capitalization
7B
Shares Outstanding
133M
Volatility Avg
21.39
Avg Vol(10 day)
1M
P/E Ratio
28.0x
EPS (TTM)
2
Annualized Rate
-- / --
Yield
0.00%
Dividend Announcement
--
Ex-Date
--
Date of Record
--
Payable
0.00 - --
Payable Date
--
Last Trade as of 1/14/2011 4:03 PM ET

Exclusive Content

When you open an account with Scottrade, you will get premium content on the News & Content page, including:

  • Standard & Poor's News and Commentary
  • Dow Jones News
  • Briefing News and Commentary
  • Market Edge On the Edge Commentary
For full analysis details, Log In with Scottrade or you can:
 
 
 

WPI Watson Pharmaceuticals Incorporated vs. Peers

Peers 
WPI
Watson Pharmaceuticals Incorporated
0.43%
MYL
Mylan Inc.
7.90%
COV
Covidien plc
3.88%
MCK
McKesson Corporation
5.39%
ABC
AmerisourceBergen Corp.
3.84%
WPI
Watson Pharmaceuticals Incorporated
0.00%
MYL
Mylan Inc.
--
COV
Covidien plc
1.69%
MCK
McKesson Corporation
0.97%
ABC
AmerisourceBergen Corp.
1.13%
WPI
Watson Pharmaceuticals Incorporated
-0.84%
MYL
Mylan Inc.
0.31%
COV
Covidien plc
0.23%
MCK
McKesson Corporation
-0.31%
ABC
AmerisourceBergen Corp.
0.14%
Compare these stocks
 
 
 
© 2011 Scottrade

Brokerage Products and Services offered by Scottrade, Inc. - Member FINRA and SIPC

Online market and limit stock trades are just $7 for stocks priced $1 and above.

Any specific securities, or types of securities, used as examples are for demonstration purposes only. No information on this Web site should be considered a recommendation or None of the information provided should be considered a recommendation or solicitation to invest in, or liquidate, a particular security or type of security.

Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund carefully before investing. A mutual fund's prospectus contains this and other information about the mutual fund. Prospectuses are available through our trading site or through a Scottrade Branch Office. The prospectus should be read carefully before investing. No transaction fee (NTF) funds are subject to the terms and conditions of the NTF funds program. Scottrade is compensated by the funds participating in the NTF program through recordkeeping, shareholder, or SEC 12b-1 fees.

Investors should consider the investment objectives, charges, expense, and unique risk profile of an Exchange Traded Fund (ETF) carefully before investing. Leveraged and Inverse ETFs may not be suitable for long-term investors and may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies. A prospectus contains this and other information about the ETF and should be obtained from the issuer. The prospectus should be read carefully before investing.

Margin trading involves interest charges and risks, including the potential to lose more than deposited, or the need to deposit additional collateral in a falling market. Margin Disclosure Statement (PDF) is available for download, or it is available at one of our branch offices. It contains information on our lending policies, interest charges, and the risks associated with margin accounts.

Options involve risk and are not suitable for all investors. Detailed information on our policies and the risks associated with options can be found in the Scottrade Options Application and Agreement, Brokerage Account Agreement, and by downloading the Characteristics and Risks of Standardized Options and Supplements (PDF) from The Options Clearing Corporation, or by requesting a copy from your local branch office. Supporting documentation for any claims will be supplied upon request.

Market volatility, volume, and system availability may impact account access and trade execution.

Testimonials may not be representative of the experience of other clients and are no guarantee of future performance or success.